Examkin

Question

Difficulty: Very hardMonitoring and Treatment Evaluation

A 32-year-old man is evaluated in the outpatient clinic for increased thirst and frequent urination over the past 3 months. He reports drinking approximately 6 to 8 liters of water daily and waking up 3 to 4 times per night to urinate. His medical history is significant for bipolar I disorder. He has had multiple severe manic episodes with psychotic features in the past, which required prolonged hospitalizations. Trials of divalproex sodium, carbamazepine, and atypical antipsychotics were ineffective in preventing relapses. For the past 4 years, he has been completely stable with no mood episodes on a regimen of lithium carbonate 900 mg900 \text{ mg} daily. He takes no other medications.

Vital signs are within normal limits. Physical examination reveals mild dry mucous membranes but is otherwise unremarkable.

Laboratory results are as follows:
Serum sodium: 146 mEq/L146 \text{ mEq/L}
Serum potassium: 4.1 mEq/L4.1 \text{ mEq/L}
Serum creatinine: 1.0 mg/dL1.0 \text{ mg/dL}
Serum lithium: 0.9 mEq/L0.9 \text{ mEq/L} (therapeutic range: 0.6−1.2 mEq/L0.6-1.2 \text{ mEq/L})
Serum osmolality: 298 mOsm/kg H2O298 \text{ mOsm/kg H}_2\text{O}
Urine osmolality: 120 mOsm/kg H2O120 \text{ mOsm/kg H}_2\text{O}

Following a formal water deprivation test, his urine osmolality remains low and does not significantly increase after the administration of subcutaneous desmopressin.

Given the patient's psychiatric history and current stability, which of the following is the most appropriate next step in the management of this patient's new symptoms?

  1. A
    Add oral hydrochlorothiazide
  2. B
    Discontinue lithium and initiate divalproex sodium
  3. Add oral amilorideAnswer
  4. D
    Add intranasal desmopressin
  5. E
    Advise restriction of free water intake to 1.5 L1.5 \text{ L} daily

Answer

Add oral amiloride
The correct answer involves adding oral amiloride while maintaining the current lithium therapy. The patient has developed lithium-induced nephrogenic diabetes insipidus (NDI), confirmed by polyuria, polydipsia, high-normal serum sodium, and a failure to concentrate urine after water deprivation and desmopressin administration. Because his severe bipolar disorder is exceptionally well-controlled on lithium after failing multiple other therapies, discontinuing lithium carries a very high risk of psychiatric relapse. The most appropriate next step is to manage the adverse effect. Lithium enters the principal cells of the renal collecting duct through the epithelial sodium channel (ENaC), where it interferes with cyclic AMP generation and prevents the insertion of aquaporin-2 water channels. Amiloride is a potassium-sparing diuretic that directly blocks ENaC, thereby preventing lithium from entering the principal cells. This specific mechanism ameliorates the NDI without significantly altering systemic lithium clearance or necessitating a dose change.

Step-by-Step Solution

1
Interpret the clinical presentation and laboratory results.
The patient exhibits polyuria, high-normal serum sodium, and inappropriately dilute urine that does not concentrate after desmopressin administration, confirming the diagnosis of nephrogenic diabetes insipidus (NDI).
Establishing the exact mechanism of polyuria (nephrogenic vs. central DI vs. primary polydipsia) is essential to guide appropriate therapy.
2
Identify the etiology of the NDI.
The patient's chronic lithium therapy is identified as the underlying cause, as lithium interferes with aquaporin-2 channel insertion in the renal collecting ducts.
Lithium is the most common cause of drug-induced NDI, entering the principal cells via the epithelial sodium channel (ENaC).
3
Evaluate the current therapeutic regimen and risk of alteration.
The patient has severe, treatment-refractory bipolar disorder but has achieved long-term stability on lithium. Discontinuing lithium carries an unacceptably high risk of manic relapse.
Therapeutic stability must be carefully weighed against medication side effects when evaluating ongoing treatment plans.
4
Select the optimal targeted pharmacologic adjunct.
Amiloride is selected to manage the side effect because it blocks ENaC, preventing lithium from entering the principal cells without altering systemic lithium clearance.
Amiloride provides a mechanism-specific antidote for lithium-induced NDI while allowing the patient to safely continue their life-saving psychiatric medication.

Key Concept

Amiloride is the specific treatment of choice for lithium-induced nephrogenic diabetes insipidus (NDI) because it blocks the epithelial sodium channel (ENaC) in the collecting duct, thereby preventing lithium entry into principal cells without precipitating systemic lithium toxicity.
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic